Search Results - Naoki Furuya

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Repeating late-phase pseudo-progression in a patient with non-small cell lung cancer treated with long-term nivolumab monotherapy; a case report by Rikako Ebisuda, Naoki Furuya, Takeo Inoue, Shotaro Kaneko, Yu Numata, Yusuke Shinozaki, Masamichi Mineshita

    Published in Frontiers in Oncology (2024-07-01)
    Get full text
    Article


  2. 2

    Recent advances in therapeutic strategies for non-small cell lung cancer by Po-Lan Su, Naoki Furuya, Alahmadi Asrar, Christian Rolfo, Zihai Li, David P. Carbone, Kai He

    Published in Journal of Hematology & Oncology (2025-03-01)
    Get full text
    Article


  3. 3

    Cancer cell immunity-related protein co-expression networks are associated with early-stage solid-predominant lung adenocarcinoma by Toshihide Nishimura, Ákos Végvári, Haruhiko Nakamura, Kiyonaga Fujii, Kiyonaga Fujii, Hiroki Sakai, Saeko Naruki, Naoki Furuya, Hisashi Saji

    Published in Frontiers in Oncology (2024-02-01)
    Get full text
    Article


  4. 4

    DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy by Po-Lan Su, Karthik Chakravarthy, Naoki Furuya, Jeremy Brownstein, Jianhua Yu, Meixiao Long, David Carbone, Zihai Li, Kai He

    Published in Molecular Cancer (2024-05-01)
    Get full text
    Article


  5. 5

    Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising‐VTE/NEJ037 Study by Naoki Furuya, Yukari Tsubata, Takamasa Hotta, Toshihide Yokoyama, Masahiro Yamasaki, Nobuhisa Ishikawa, Kazunori Fujitaka, Tetsuya Kubota, Kunihiko Kobayashi, Takeshi Isobe

    Published in Cancer Medicine (2025-01-01)
    Get full text
    Article


  6. 6

    Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non–Small-Cell Lung Cancer by Tomoyuki Miyazawa, Kanji Otsubo, Hiroki Sakai, Hiroyuki Kimura, Motohiro Chosokabe, Kei Morikawa, Naoki Furuya, Hideki Marushima, Koji Kojima, Masamichi Mineshita, Junki Koike, Hisashi Saji

    Published in Cancer Control (2021-08-01)
    Get full text
    Article


  7. 7

    Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometas... by Takaaki Tokito, Kazuhiko Yamada, Hidenobu Ishii, Yuichi Takiguchi, Go Saito, Koichi Minato, Hisao Imai, Hiroshi Tanaka, Satoru Miura, Kageaki Watanabe, Yoshifusa Koreeda, Akira Ono, Naoki Furuya, Toshihiro Misumi, Kazushige Hayakawa, Etsuyo Ogo, Hiroaki Okamoto

    Published in Radiation Oncology (2025-01-01)
    Get full text
    Article


  8. 8

    Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer by Hirotaka Matsumoto, Hiroaki Akamatsu, Nobuyuki Yamamoto, Yuki Sato, Daichi Fujimoto, Yoshihiko Taniguchi, Motohiro Tamiya, Yasuhiro Koh, Junya Fukuoka, Hisashi Tanaka, Naoki Furuya, Ryota Shibaki, Tsukasa Nozawa, Akira Sano, Yuka Kitamura, Takashi Kijima, Toshihide Yokoyama, Satoru Miura, Akito Hata, Jun Sugisaka

    Published in Journal for ImmunoTherapy of Cancer (2024-02-01)
    Get full text
    Article


  9. 9

    Impact of Cachexia and First‐Line Systemic Therapy for Previously Untreated Advanced Non‐Small Cell Lung Cancer: NEJ050A by Keita Miura, Takehito Shukuya, Naoki Furuya, Ryo Morita, Akira Kisohara, Atsuto Mouri, Satoshi Watanabe, Hisashi Tanaka, Aya Hirata, Taiki Hakozaki, Kosuke Hamai, Naoko Matsumoto, Kana Watanabe, Hironori Ashinuma, Eisaku Miyauchi, Koji Sugano, Shinobu Hosokawa, Koji Amano, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemonodo, Kazuhisa Takahashi

    Published in Journal of Cachexia, Sarcopenia and Muscle (2024-12-01)
    Get full text
    Article


  10. 10

    Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study by Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Prof Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Prof Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Prof Koichi Hagiwara, Prof Toshihiro Nukiwa, Prof Satoshi Morita, Prof Kunihiko Kobayashi, Prof Makoto Maemondo

    Published in EBioMedicine (2020-07-01)
    Get full text
    Article


  11. 11

    Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

    Published in JTO Clinical and Research Reports (2025-03-01)
    Get full text
    Article


Search Tools: